{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:59:38Z","timestamp":1778626778666,"version":"3.51.4"},"reference-count":76,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.trecan.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T00:42:00Z","timestamp":1471999320000},"page":"467-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Malignant Mesothelioma: Time to Translate?"],"prefix":"10.1016","volume":"2","author":[{"given":"Andrea","family":"Napolitano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2016.07.004_bib0385","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.trecan.2016.07.004_bib0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1179\/2049396712Y.0000000016","article-title":"Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008","volume":"19","author":"Henley","year":"2013","journal-title":"Int. J. Occup. Environ. Health"},{"key":"10.1016\/j.trecan.2016.07.004_bib0395","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","article-title":"Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma","volume":"18","author":"Carbone","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2016.07.004_bib0400","first-page":"566","article-title":"The mortality of amphibole miners in South Africa, 1946-80","volume":"49","author":"Sluis-Cremer","year":"1992","journal-title":"Br. J. Ind. Med."},{"key":"10.1016\/j.trecan.2016.07.004_bib0405","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1586\/17476348.2015.1081066","article-title":"Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies","volume":"9","author":"Bononi","year":"2015","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.trecan.2016.07.004_bib0410","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus Report of the 2015 Weinman International Conference on Mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2016.07.004_bib0415","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2016.07.004_bib0420","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2016.07.004_bib0425","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial","volume":"16","author":"Stahel","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2016.07.004_bib0430","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2016.07.004_bib0435","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2016.07.004_bib0440","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(00)04013-7","article-title":"Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey","volume":"357","author":"Roushdy-Hammady","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2016.07.004_bib0445","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trecan.2016.07.004_bib0450","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2016.07.004_bib0455","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/ng.910","article-title":"Germline mutations in BAP1 predispose to melanocytic tumors","volume":"43","author":"Wiesner","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trecan.2016.07.004_bib0460","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.trecan.2016.07.004_bib0465","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/cge.12472","article-title":"Germline BAP1 mutations predispose also to multiple basal cell carcinomas","volume":"88","author":"de la Fouchardiere","year":"2015","journal-title":"Clin. Genet."},{"key":"10.1016\/j.trecan.2016.07.004_bib0470","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cge.12501","article-title":"A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma","volume":"88","author":"Wadt","year":"2015","journal-title":"Clin. Genet."},{"key":"10.1016\/j.trecan.2016.07.004_bib0475","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/1541-7786.MCR-13-0111","article-title":"A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma","volume":"11","author":"Farley","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.trecan.2016.07.004_bib0480","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ajhg.2013.04.012","article-title":"Germline BAP1 mutations predispose to renal cell carcinomas","volume":"92","author":"Popova","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.trecan.2016.07.004_bib0105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.trecan.2016.07.004_bib0110","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/onc.2015.243","article-title":"Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma","volume":"35","author":"Napolitano","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2016.07.004_bib0115","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","article-title":"Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2016.07.004_bib0120","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1158\/0008-5472.CAN-15-3371","article-title":"Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations","volume":"76","author":"Kadariya","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2016.07.004_bib0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.gene.2015.03.031","article-title":"Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma","volume":"563","author":"Sneddon","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.trecan.2016.07.004_bib0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2014.10.017","article-title":"Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases","volume":"87","author":"Rusch","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.trecan.2016.07.004_bib0135","doi-asserted-by":"crossref","first-page":"e1005633","DOI":"10.1371\/journal.pgen.1005633","article-title":"Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s","volume":"11","author":"Carbone","year":"2015","journal-title":"PLoS Genet."},{"key":"10.1016\/j.trecan.2016.07.004_bib0140","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trecan.2016.07.004_bib0145","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2016.07.004_bib0150","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.trecan.2016.07.004_bib0155","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2016.07.004_bib0160","first-page":"2331","article-title":"Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma","volume":"36","author":"Ugurluer","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.trecan.2016.07.004_bib0165","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2016.07.004_bib0170","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trecan.2016.07.004_bib0175","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"de Reynies","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2016.07.004_bib0485","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2016.07.004_bib0185","doi-asserted-by":"crossref","first-page":"13757","DOI":"10.18632\/oncotarget.3765","article-title":"Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors","volume":"6","author":"Sacco","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2016.07.004_bib0190","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2016.07.004_bib0195","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2016.07.004_bib0200","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1128\/MCB.01578-08","article-title":"Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling","volume":"29","author":"Lopez-Lago","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.trecan.2016.07.004_bib0205","doi-asserted-by":"crossref","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2016.07.004_bib0210","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"25","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2016.07.004_bib0215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2014.05.001","article-title":"Merlin\/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus","volume":"26","author":"Li","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2016.07.004_bib0220","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1593\/neo.08642","article-title":"The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP","volume":"10","author":"Striedinger","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.trecan.2016.07.004_bib0225","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.molonc.2014.08.005","article-title":"The p53\/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours","volume":"9","author":"Ammoun","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.trecan.2016.07.004_bib0230","doi-asserted-by":"crossref","first-page":"e1786","DOI":"10.1038\/cddis.2015.153","article-title":"Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression","volume":"6","author":"Yang","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.trecan.2016.07.004_bib0235","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2016.07.004_bib0240","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1080\/21645515.2015.1050572","article-title":"Preclinical development of HIvax: human survivin highly immunogenic vaccines","volume":"11","author":"Hoffmann","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.trecan.2016.07.004_bib0245","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/cgt.2010.10","article-title":"Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy","volume":"17","author":"Li","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.trecan.2016.07.004_bib0490","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrd3375","article-title":"Trial watch: phase III and submission failures: 2007-2010","volume":"10","author":"Arrowsmith","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2016.07.004_bib0255","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2016.07.004_bib0260","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabro","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.trecan.2016.07.004_bib0495","series-title":"AstraZeneca Reports Top-Line Result of Tremelimumab Monotherapy Trial in Mesothelioma, AstraZeneca","author":"AstraZeneca","year":"2016"},{"key":"10.1016\/j.trecan.2016.07.004_bib0500","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/thoraxjnl-2014-206464","article-title":"Inconsistent results or inconsistent methods?. A plea for standardisation of biomarker sampling in mesothelioma studies","volume":"70","author":"Blyth","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.trecan.2016.07.004_bib0275","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12967-014-0301-3","article-title":"Evaluation of clonal origin of malignant mesothelioma","volume":"12","author":"Comertpay","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.trecan.2016.07.004_bib0280","doi-asserted-by":"crossref","first-page":"13464","DOI":"10.18632\/oncotarget.7229","article-title":"Targeting hypoxic response for cancer therapy","volume":"7","author":"Paolicchi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2016.07.004_bib0285","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1470-2045(13)70257-2","article-title":"Asbestos is not just asbestos: an unrecognised health hazard","volume":"14","author":"Baumann","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2016.07.004_bib0505","series-title":"Shorter Oxford English Dictionary","year":"2002"},{"key":"10.1016\/j.trecan.2016.07.004_bib0510","unstructured":"Pliny the Elder (AD 77) Natural History"},{"key":"10.1016\/j.trecan.2016.07.004_bib0300","doi-asserted-by":"crossref","first-page":"E1330","DOI":"10.1073\/pnas.1110013108","article-title":"Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis","volume":"108","author":"Nagai","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.trecan.2016.07.004_bib0305","first-page":"875","article-title":"Simian virus 40: the link with human malignant mesothelioma is well established","volume":"20","author":"Carbone","year":"2000","journal-title":"Anticancer Res."},{"key":"10.1016\/j.trecan.2016.07.004_bib0310","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3816\/CLC.2003.n.031","article-title":"Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40","volume":"5","author":"Gazdar","year":"2003","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.trecan.2016.07.004_bib0315","doi-asserted-by":"crossref","first-page":"e104848","DOI":"10.1371\/journal.pone.0104848","article-title":"Increased levels of C-C chemokine RANTES in asbestos exposed workers and in malignant mesothelioma patients from an hyperendemic area","volume":"9","author":"Comar","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.trecan.2016.07.004_bib0320","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/cas.12687","article-title":"Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: a patient-based study","volume":"106","author":"Xu","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.trecan.2016.07.004_bib0325","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1158\/1055-9965.EPI-07-0607","article-title":"Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study","volume":"17","author":"Amati","year":"2008","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.trecan.2016.07.004_bib0330","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.mrgentox.2008.06.011","article-title":"Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk","volume":"655","author":"Amati","year":"2008","journal-title":"Mutat. Res."},{"key":"10.1016\/j.trecan.2016.07.004_bib0335","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1383-5718(00)00053-X","article-title":"Levels of 8-hydroxy-2\u2032-deoxyguanosine in DNA of white blood cells from workers highly exposed to asbestos in Germany","volume":"468","author":"Marczynski","year":"2000","journal-title":"Mutat. Res."},{"key":"10.1016\/j.trecan.2016.07.004_bib0340","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.lungcan.2012.03.024","article-title":"Peroxiredoxins and tropomyosins as plasma biomarkers for lung cancer and asbestos exposure","volume":"77","author":"Rostila","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.trecan.2016.07.004_bib0345","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00408-016-9868-1","article-title":"Evaluation of new biomarkers in the prediction of malignant mesothelioma in subjects with environmental asbestos exposure","volume":"194","author":"Demir","year":"2016","journal-title":"Lung"},{"key":"10.1016\/j.trecan.2016.07.004_bib0350","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2016.07.004_bib0355","doi-asserted-by":"crossref","first-page":"e004145","DOI":"10.1136\/bmjopen-2013-004145","article-title":"Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis","volume":"4","author":"Cui","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.trecan.2016.07.004_bib0360","first-page":"1289","article-title":"Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis","volume":"7","author":"Lin","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.trecan.2016.07.004_bib0365","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2016.07.004_bib0370","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.trecan.2016.07.004_bib0375","first-page":"2016","article-title":"HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients","author":"Napolitano","year":"2016","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.trecan.2016.07.004_bib0380","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12014-016-9103-3","article-title":"ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms","volume":"13","author":"Morre","year":"2016","journal-title":"Clin. Proteomics"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803316300838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803316300838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T02:25:49Z","timestamp":1536459949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803316300838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S2405803316300838"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2016.07.004","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignant Mesothelioma: Time to Translate?","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}